GlassScriptPhysician profile
Allison J Roberts
NPI 1225309883
$4,428.02
in general payments reported to CMS, 2019-2025
30 companies · $783 in 2025
The $783 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $759 · 2022: $1,001 · 2023: $1,015 · 2024: $870 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.87 |
| Education | $159.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $888.44 | 2021-2025 | |
| Amgen INC. | $541.92 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $297.54 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $294.05 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $276.90 | 2021-2025 | Odomzo, Blu-U, Winlevi |
| Lilly USA, LLC | $232.93 | 2021-2025 | Zepbound, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $166.72 | 2023-2024 | Sotyktu |
| Incyte Corporation | $140.51 | 2023-2024 | Opzelura |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $124.80 | 2024 | Rexulti |
| Cti Biopharma Corp. | $124.80 | 2023 | Vonjo |
| Horizon Therapeutics Plc | $123.42 | 2021 | |
| Alnylam Pharmaceuticals INC. | $122.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $121.50 | 2022 | |
| Janssen Scientific Affairs, LLC | $121.11 | 2022-2023 | Stelara |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $107.76 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $107.58 | 2022 | |
| Grifols USA, LLC | $100.00 | 2022 | |
| Ucb, INC. | $85.93 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $58.95 | 2022-2024 | |
| Novo Nordisk INC | $42.47 | 2021-2024 | Ozempic |
| Biofrontera INC. | $36.19 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Dexcom, INC. | $35.69 | 2025 | Dexcom G6 Transmitter |
| Fresenius Kabi USA, LLC | $30.48 | 2023 | Idacio |
| Genentech USA, INC. | $29.64 | 2022 | |
| Abbott Laboratories | $23.46 | 2025 | Cardiomems |
| Regeneron Healthcare Solutions, INC. | $19.56 | 2022 | |
| Leo Pharma INC. | $17.65 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.11 | 2021 | |
| Kerecis Limited | $13.21 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.